Canaccord lowered the firm’s price target on Curaleaf (CURLF) to C$5 from C$6 and keeps a Buy rating on the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CURLF:
- Curaleaf Intl secures regulatory approval for handheld liquid inhalation device
- Curaleaf Holdings’ Mixed Q1: Growth Amid Challenges
- Curaleaf Holdings Reports Q1 2025 Financial Results
- Curaleaf Holdings Reports Q1 2025 Results with Strong International Growth
- Curaleaf reports Q1 adjusted cont ops EPS (7c) vs. (6c) last year